Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06131203 · ClinicalTrials.gov registry record
Burn Validation Study
A clinical trial, sponsored by SpectralMD.
- Completed
- Registry status
- 274
- Enrollment target
NCT06131203: Completed study, sponsored by SpectralMD.
NCT06131203 is a clinical trial that has completed, run by SpectralMD. The registered enrollment target is 274 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06131203 has completed, sponsored by SpectralMD.
- COMPLETED
- Registry status
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to validate the algorithm for burn healing assessment by the Spectral MD DeepView device which would provide burn healing potential assessment.
Primary Outcome
Demonstrate the DeepView AI-Burns' sensitivity is superior to BC HCPs' bedside examination while maintaining non-inferior specificity to burn HCPs.
Interventions
- DEVICE DeepView SnapShot Portable (DV-SSP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2025-04-01 |
What the finished NCT06131203 record still lists
NCT06131203 is an observational study that tracks outcomes without assigning an intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which DeepView SnapShot Portable (DV-SSP) is the first listed.
NCT06131203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06131203 about?
NCT06131203 is a clinical study titled "Burn Validation Study". The purpose of this study is to validate the algorithm for burn healing assessment by the Spectral MD DeepView device which would provide burn healing potential assessment.
What is the current status of trial NCT06131203?
This trial is currently completed. The enrollment target is 274 participants. The study started on 2023-12-19. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT06131203?
The interventions under investigation include: DeepView SnapShot Portable (DV-SSP) (DEVICE).
Who is sponsoring clinical trial NCT06131203?
This trial is sponsored by SpectralMD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI